Navigation Links
AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
Date:8/17/2012

LOS ALTOS, Calif., Aug. 17, 2012 /PRNewswire-iReach/ -- AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.

(Photo: http://photos.prnewswire.com/prnh/20120817/CG59299)

Our antibody demonstrated a great safety profile in preclinical safety and phase 1 clinical trial studies in both psoriasis patients and healthy volunteers. In SRD phase 1 psoriasis patient study, a clear biological/pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was demonstrated in patients. The current Phase 2 clinical trial of AbGn-168H will be a multicenter, placebo-controlled, double-blind trial. The primary objective of the study is to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect in psoriatic patients. Additional clinical trials for type-I diabetes, Crohn's and other autoimmune diseases are under evaluation.

About AbGenomics (www.abgenomics.com)

AbGenomics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. Currently, the company has two therapeutic candidates in clinical trials. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds.

Media Contact: RUTH LI ABGENOMICS INTERNATIONAL INC., 6509889912, ABG@ABGENOMICS.COM

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE AbGenomics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Chindex International, Inc. to Report First Quarter 2012 Financial Results
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Bacterin International Signs Its Third National GPO Contract with Novation
11. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  A recent study at ... four freestanding hospitals in the country dedicated to the ... reconstructive surgery, concluded that the Surfacide Helios ® ... component in reducing bacterial pathogens not killed by the ... published at the American Burn Association,s 49th Annual Meeting ...
(Date:3/27/2017)... 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... shares of common stock in an underwritten public offering ... the Securities and Exchange Commission (the "SEC"). The offering ... can be no assurance as to whether or when ... actual size or terms of the offering. Cryoport also ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Public relations ... and across a variety of business channels. , While many results are clear, much ... public relations program. , When it comes to measurement, firms should always take ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/28/2017)... ... 2017 , ... Bacteria and fungi are probably not the first ingredients that come to mind ... right microorganisms in your diet can actually improve health outcomes. And the good news is ... topic of a new peer-reviewed paper led by Maria Marco, Ph.D. , ...
(Date:3/27/2017)... Ohio (PRWEB) , ... March 27, 2017 , ... New ... OH to replace their missing teeth can now have them placed by Dr. Manju ... the latest i-CAT® Cone Beam technology to increase the accuracy of each dental implant ...
(Date:3/27/2017)... ... ... A study by the founder of the Buckingham Center for Facial Plastic ... published in the American Journal of Cosmetic Surgery. “The Effects of an Antistick Phospholipid ... the use of Electro Lube during the facelift procedure. The journal, a publication of ...
Breaking Medicine News(10 mins):